Home > Press > Stellar Biotechnologies’ Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology
Abstract:
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the technology developed through a Collaborative Research Agreement between Stellar and Bayer Innovations (BIG).
Stellar Biotechnologies’ Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology
Port Hueneme, CA | Posted on December 7th, 2010
The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development. Otherwise, the license leaves Stellar free to commercialize the technology, exclusively, in all other fields.
Stellar CEO, Frank Oakes said, "The technology developed through the collaboration with BIG represents a breakthrough in the production of highly characterized, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product. The technology will be integrated into BIG's NHL vaccine platform, and commercialized broadly by Stellar for other vaccines and related products."
Stellar's CEO letter to shareholders, dated 11/24/10, has been posted:
www.stellarbiotechnologies.com/investors/shareholders/index.php?&content_id=54
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.
####
About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
For more information, please click here
Contacts:
Darrell Brookstein
Copyright © Stellar Biotechnologies
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013
Nanomedicine
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013
Patents/IP/Tech Transfer/Licensing
NanoInk, Inc. Assets To Be Sold May 18th, 2013
HELIOS Program Develops Complete Supply Chain for Integrating Photonics with CMOS Circuit via IC Fabrication Processes May 14th, 2013
Nanotechnology Pioneer Named 'Entrepreneur of the Year': Royal Society of Chemistry honors Chad Mirkin for commercializing innovations May 10th, 2013
Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone May 7th, 2013
Nanobiotechnology
Researchers Perform Fastest Measurements Ever Made of Ion Channel Proteins May 20th, 2013
Artificial Forest for Solar Water-Splitting: Berkeley Lab Researchers Report First Fully Integrated Artificial Photosynthesis Nanosystem May 17th, 2013
Glowing Plant Kickstarter Project Retains Digital Marketing Agency, Command Partners: Glowing Plant brings on top Charlotte-based digital marketing firm to assist in crowdfunding campaign May 16th, 2013
DNA-Guided Assembly Yields Novel Ribbon-Like Nanostructures: Approach could be useful in fabricating new kinds of materials with engineered properties May 16th, 2013